SUR1 also confers the KATP channel with its sensitivity and response to sulfonylureas such as glibenclamide (18) and channel activators such a diazoxide, which is commonly used to treat medically responsive CHH (19). The gene discussed is ABCC8; the disease is cartilage-hair hypoplasia.